EGFR and adenocarcinoma: Adenocarcinoma in particular has the most identified actionable mutations, as evidenced by the approval of multiple targeted therapies directed against EGFR, ALK, ROS1, BRAF V600 and NTRK aberrations [14,15,16,17,18].